Search

Methods to generate stem cells have given scientists new ways to study some diseases and identify potential drugs, and could one day be used to rebuild diseased or damaged tissues in patients.

… Tuesday, December 11, 2012 Summary Methods to generate stem cells have given scientists new ways to study some diseases and identify potential drugs, and could one day be used to rebuild diseased or damaged tissues in patients. On December 10, John B. Gurdon of the University of Cambridge and Shinya

Understanding tumor heterogeneity may be the next big quest in cancer science, as differences between cells within a tumor can have important consequences for how cancers are diagnosed and treated.

… Wednesday, July 2, 2014 Summary Understanding tumor heterogeneity may be the next big quest in cancer science, as differences between cells within a tumor can have important consequences for how cancers are diagnosed and treated. Every person’s cancer develops and grows in its own way and is unique in

In honor of Women's History Month, meet the scientific hero who helped build MSK's molecular biology program.

… Wednesday, March 13, 2019 Ora Rosen Ora Rosen, an expert in insulin signaling, co-founded the Molecular Biology Program at the Sloan Kettering Institute. Ora Rosen Dr. Rosen (right) with graduate students Roman Herrera and Lilli Petruzzelli Summary In honor of Women’s History Month, we’re remembering

Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after the disease becomes resistant to standard treatments.

… Tuesday, December 1, 2009 Summary Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after the disease becomes resistant to standard treatments. Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after

New research from MSK develops a method for analyzing cancer cells that survive treatment for acute myeloid leukemia; identifies a transcription factor that orchestrates natural killer cell response; and finds vepafestinib is a promising therapeutic for the treatment of RET-driven cancers.

… Friday, September 29, 2023 New research from Memorial Sloan Kettering Cancer Center (MSK) develops a method for analyzing cancer cells that survive treatment for acute myeloid leukemia; identifies a transcription factor that orchestrates natural killer cell response; and finds vepafestinib is a promising

New research from MSK explores novel predictors of immunotherapy effectiveness against lung cancer; identifies how a high-fat diet hinders intestinal damage repair; reports findings from a clinical trial for people with androgen receptor-positive salivary gland cancer; and aims to understand the impact of tumor mutational burden on patients with locally advanced non-small cell lung cancer.

… Friday, January 20, 2023 New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute — MSK’s experimental research arm — explores novel predictors of immunotherapy effectiveness against lung cancer; identifies how a high-fat diet hinders intestinal damage repair;

Why do some patients respond to immunotherapy while others do not? Blood may hold the answer.

… Monday, April 10, 2017 Summary Some patients who receive immunotherapy drugs called checkpoint inhibitors experience significant benefit in terms of tumor shrinkage and longer survival — but many do not. A new study suggests that measuring changes in the blood could help doctors determine whether a person

A team of researchers from MSK and Weill Cornell Medicine is expanding the understanding of how a decades-old treatment for bladder cancer works — an understanding that could help improve the effectiveness of immunotherapies more broadly.

… Thursday, May 29, 2025 More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat early-stage bladder cancer. Now, a team of researchers from Memorial Sloan Kettering Cancer

Electronic nose (e-nose) technology identified early-stage lung cancer with high reliability in a prospective observational clinical trial conducted at Memorial Sloan Kettering Cancer Center (MSK).

… Friday, June 7, 2024 Electronic nose (e-nose) technology identified early-stage lung cancer with high reliability in a prospective observational clinical trial conducted at Memorial Sloan Kettering Cancer Center (MSK). E-nose diagnostic predictions agreed with histopathological results in 86% of 100

Pancreatic cancer cells spread with the help of tracks laid by nerve-supporting cells called Schwann cells.

… Wednesday, August 3, 2022 Cancer relies on many tricks to survive and grow. One tactic is to manipulate cells in the noncancerous tissues and cells surrounding a tumor to help the cancer cells spread. Researchers have learned that cancer seems to have a particular fondness for nerves, traveling along